Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
View Patent ↗The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen.
1. An isolated and purified hemorrhagic feline calicivirus FCV-DD1, wherein the strain has ATCC Patent Deposit Designation PTA-6204 or a viral clone derived therefrom.
2. An immunogenic composition comprising an immunologically effective amount of the feline calicivirus according to claim 1 .
3. A vaccine comprising a nontoxic, physiologically acceptable carrier or diluent and the immunogenic composition according to claim 2 .
4. The vaccine according to claim 3 , further comprising one or more additional feline calicivirus(es).
5. The vaccine according to claim 4 , wherein the additional feline calicivirus is selected from the group consisting of FCV-255, FCV-2280, FCV-Diva, FCV-Kaos, FCV-Bellingham, FCV-F9, FCV-F4, FCV-M8 and a combination thereof.
6. The vaccine according to claim 5 , wherein the additional feline calicivirus comprises FCV-255, FCV-2280 or the combination of FCV-255 and FCV-2280.
7. The vaccine according to claim 6 , wherein the additional feline calicivirus comprises FCV-255.
8. The vaccine according to claim 6 , further comprising an antigen selected from the group consisting of Chlamydophila felis , feline leukemia virus, feline panleukopenia virus, feline rhinotracheitis virus, feline immunodeficiency virus, rabies virus, feline infectious peritonitis virus, Bartonella and a combination thereof.
9. The vaccine according to claim 8 , wherein the antigen comprises the combination of Chlamydophila felis , feline leukemia virus, feline panleukopenia virus and feline rhinotracheitis virus.
10. The vaccine according to claim 8 , wherein the antigen comprises the combination of Chlamydophila felis , and feline rhinotracheitis virus.
11. The vaccine according to claim 8 wherein the antigen comprises the combination of feline panleukopenia virus and feline rhinotracheitis virus.
12. The vaccine according to claim 8 further comprsing an adjuvant.
13. The vaccine according to claim 12 , wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum hydroxide, a surfactant, a polyanion, a polycation, a detergent, a peptide, a metabolizable animal or vegetable oil, a mineral oil, a mineral oil emulsion, an immunomodulator, a polyoxyethylene-polyoxpropylene block copolymer, a copolymer of styrene with a mixture of acrylic acid and methacrylic acid, a Corynebacterium-derived adjuvant, a Propionibacterium-derived adjuvant, Mycobacterium bovis (Bacille Calmette-Guerin), an interleukin, an interferon, a liposome, an iscom adjuvant, a mycobacterial cell wall extract, a synthetic glycopeptide, avridine, Lipid A, dextran sulfate, DEAE-Dextran, carboxypolymethylene, ethylene/maleic anhydride copolymer, an acrylic copolymer emulsion, an animal poxvirus protein, a subviral particle adjuvant, cholera toxin, dimethyldioctadecylammonium bromide and a combination thereof.
14. The vaccine according to claim 13 , wherein the adjuvant is an ethylene/maleic anhydride copolymer, a copolymer of styrene with a mixture of acrylic acid and methacrylic acid, a mineral oil emulsion or the combination thereof.
15. The vaccine according to claim 13 , wherein the adjuvant is saponin, squalane, squalene, the detergent, aluminum phosphate, aluminum hydroxide or the combination thereof.
16. The vaccine according to claim 8 , wherein the nontoxic, physiologically acceptable carrier or diluent comprises saline or Eagle's minimum essential media.
17. The vaccine according to claim 8 , fruther comprising a preservative.
18. The vaccine according to claim 17 , wherein the preservative is selected from the group consisting of thimerosal, neomycin, polymyxin B, amphotericin B and a combination thereof.
19. A method of protecting a feline against infection caused by feline calicivirus FCV-DD1 which comprises administering to the feline an immunologically effective amount of the vaccine according to claim 3 .
20. A method of protecting a feline against infection caused by feline calicivirus FCV-DD1 which comprises administering to the feline an immunologically effective amount of the vaccine according to claim 4 .
21. A method of protecting a feline against infection caused by feline calicivirus FCV-DD1 which comprises administering to the feline an immunologically effective amount of the vaccine according to claim 6 .
22. A method of protecting a feline against infection caused by feline calicivirus FCV-DD1, Chlamydophila felis , feline leukemia virus, feline panleukopenia virus, feline rhinotrachetis virus, feline immunodeficiency virus, rabies virus, feline infectious peritonitis virus, Bartonella or a combination thereof which comprises administering to the feline an immunologically effective amount of the vaccine according to claim 8 .
23. A method of protecting a feline against infection caused by feline calicivirus FCV-DD1, feline leukemia virus, feline panleukopenia virus, feline rhinotracheitis virus and Chlamydophila felis which comprises administering to the feline an immunologically effective amount of the vaccine according to claim 9 .
24. A method of protecting a feline against infection caused by feline calicivirus FCV-DD1, feline panleukopenia virus, feline rhinotracheitis virus and Chlamydophila felis which comprises administering to the feline an immunologically effective amount of the vaccine according to claim 10 .
25. A method of protecting a feline against infection caused by feline calicivirus FCV-DD1, feline panleukopenia virus and feline rhinotracheitis virus which comprises administering to the feline an immunologicaly effective amount of the vaccine according to claim 11 .
26. A method as in any one of claims 19 , 20 , 21 , 22 , 23 , 24 , and 25 in which the vaccine is administered parenterally, orally, intranasally, oronasally or transdermally to the feline.
27. The method according to claim 26 , wherein the vaccine is administered intramuscularly, subcutaneously or oronasally to the feline.